U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C29H34FN3O6.ClH
Molecular Weight 576.056
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Palonidipine hydrochloride

SMILES

Cl.COC(=O)C1=C(C)NC(C)=C(C1C2=C(F)C=CC(=C2)[N+]([O-])=O)C(=O)OCC(C)(C)CN(C)CC3=CC=CC=C3

InChI

InChIKey=OQHXRVQARZHYGQ-UHFFFAOYSA-N
InChI=1S/C29H34FN3O6.ClH/c1-18-24(27(34)38-6)26(22-14-21(33(36)37)12-13-23(22)30)25(19(2)31-18)28(35)39-17-29(3,4)16-32(5)15-20-10-8-7-9-11-20;/h7-14,26,31H,15-17H2,1-6H3;1H

HIDE SMILES / InChI

Molecular Formula C29H34FN3O6
Molecular Weight 539.5952
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Palonidipine (also known as TC 81) a calcium antagonist that was developed by Teijin for the treatment of hypertension and angina pectoris. Palonidipine was involved in phase II clinical trials in Japan. However, these studies were discontinued.

Approval Year

PubMed

Substance Class Chemical
Record UNII
9D73PQ95UJ
Record Status Validated (UNII)
Record Version